New lead investor in Xeltis's additional €20.5M funding tranche to advance the aXess vascular access conduit toward FDA approval and US commercial launch.
Xeltis is an international medtech company developing innovative vascular implants that transform into each patient’s living and long-lasting tissue, leveraging its proprietary Restorex® supramolecular polymer technology
Xeltis is an international medtech company developing innovative vascular implants that transform into each patient’s living and long-lasting tissue, leveraging its proprietary Restorex® supramolecular polymer technology.